benzo[i]phenanthridine | 218-16-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: benzo[i]phenanthridine
• 英文别名: Benzophenanthridin
• CAS: 218-16-6
• 化学式: C₁₇H₁₁N
• 分子量: 229.281
• InChiKey: MILBWDCEFBJDDS-UHFFFAOYSA-N

物化性质

• 熔点：
  137-138 °C
• 沸点：
  449.7±14.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  benzo[i]phenanthridine 以 乙醚 、 二氯甲烷 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  二氢吲哚并二氮杂苯的光致变色反应第七部分：带有取代的苯并[i]菲啶作为发荧光基团的新型光致变色二氢吲哚并二氮杂苯的光化学特性†

  摘要：

  通过顺-反取代的4-苯乙烯基喹啉的光环化以低至中等的产率制备了十六种苯并[i]菲啶衍生物8a-p。通过光谱和分析工具明确阐明了光环化苯并[i]菲啶衍生物的化学结构。该光致变色（PC）dihydroindolizines（DHIs）8A-P基于苯并[d]是在19-57％的收率通过亲核加成苯并[I]菲啶制备菲啶4A-P到spirocyclopropenes 5。一维，二维，NOESY NMR光谱，质谱和元素分析用于表征新合成的DHI 8a-p的化学结构。已经实现了通过基础部分中的取代基开发和调节合成化合物的光物理性质。最大吸收（λ最大）和半衰期（吨1/2有色两性离子形式的）图7a-P在所有情况下由闪光光解测量检测由于快速1,5- electrocyclization回DHI系统。在CH 2 Cl 2溶液中用多色光照射DHI 8a-p会导致在用液氮冷却后形成绿色到绿色-蓝色的甜菜碱7a-p。从甜菜碱7a-p到DHI

  DOI：

  10.1002/poc.1209
• 作为产物：
  描述：

  5-chloro-benzo[i]phenanthridine 在 氢氧化钾 、 镍 作用下， 生成 benzo[i]phenanthridine
  参考文献：
  名称：

  多核杂环系统。第八部分 施密特反应的合成应用

  摘要：

  DOI：

  10.1039/jr9540002329

文献信息

• Pharmaceutical Compositions Comprising Deuterium-Enriched Perillyl Alcohol, Iso-Perillyl Alcohol and Derivatives Thereof
  申请人：NEONC TECHNOLOGIES INC.

  公开号：US20160039731A1

  公开（公告）日：2016-02-11

  The present invention, provides for a deuterium-enriched monoterpene or sesquiterpene such as perillyl alcohol, or a deuterium-enriched isomer or analog of monoterpenes or sesquiterpenes, such as isoperillyl alcohol. The present invention also provides for a deuterium-enriched derivative of a monoterpene or sesquiterpene, such as a perillyl alcohol carbamate or a deuterium-enriched derivative of an isomer or analog of a monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The deuterium-enriched derivative may be perillyl alcohol or isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a deuterium-enriched compound.

  本发明提供了一种氘增强的单萜或倍半萜，例如桃金娘醇，或者一种氘增强的单萜或倍半萜的同系物或类似物，例如异桃金娘醇。本发明还提供了一种单萜或倍半萜的氘增强衍生物，例如桃金娘醇碳酰胺或一种单萜或倍半萜的同系物或类似物的氘增强衍生物，例如异桃金娘醇碳酰胺。所述氘增强衍生物可以是与治疗剂如化疗剂结合的桃金娘醇或异桃金娘醇。本发明还提供了一种治疗疾病如癌症的方法，包括向患者提供治疗有效量的氘增强化合物。
• [EN] COMPOSITIONS AND METHODS OF DECREASING MEDICATION ERRORS<br/>[FR] COMPOSITIONS ET MÉTHODES DESTINÉES À RÉDUIRE LES ERREURS DE MÉDICATION
  申请人：AZHC LLC

  公开号：WO2019014420A1

  公开（公告）日：2019-01-17

  The present disclosure provides for a method of decreasing medication errors by adding an odorant to a pharmaceutical composition comprising an active agent. The odorant has a distinct and characteristic odor. Thus, the pharmaceutical composition comprising the active agent can be properly identified by the characteristic odor.

  本公开提供了一种通过向包含活性成分的药物组合物中添加香料来减少药物错误的方法。该香料具有独特且特征性的气味。因此，可以通过这种特征性气味正确识别包含活性成分的药物组合物。
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES DÉRIVÉS DE POH
  申请人：NEONC TECH INC

  公开号：WO2021061752A1

  公开（公告）日：2021-04-01

  The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as a primary cutaneous lymphoma which may be a cutaneous T cell lymphoma (CTCL). The CTCL may be mycosis fungoides, primary cutaneous anaplastic large cell lymphoma (ALCL), or Sezary syndrome. A patient may be administered a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene).

  本发明提供了一种单萜或倍半萜的衍生物，例如一种胡椒醇衍生物。例如，该胡椒醇衍生物可以是胡椒醇碳酰胺。胡椒醇衍生物可以是胡椒醇与治疗剂如化疗药物结合的产物。本发明还提供了一种治疗疾病的方法，例如原发皮肤淋巴瘤，可能是皮肤T细胞淋巴瘤（CTCL）。CTCL可能是真菌病样皮肤T细胞淋巴瘤、原发皮肤间变性大细胞淋巴瘤（ALCL）或塞扎里综合征。可以向患者施用一种单萜（或倍半萜）衍生物的治疗有效量。
• A new synthetic approach to 6-unsubstituted phenanthridine and phenanthridine-like compounds under mild and metal-free conditions
  作者：Jumreang Tummatorn、Suppachai Krajangsri、Krissada Norseeda、Charnsak Thongsornkleeb、Somsak Ruchirawat

  DOI：10.1039/c4ob00797b

  日期：——

  A new and mild synthetic approach for the synthesis of 6-unsubstituted phenanthridine and phenanthridine-like compounds under metal-free conditions at room temperature has been developed. The strategy involved a tandem azide rearrangement/intramolecular annulation and oxidation reactions of biarylmethyl azide precursors to obtain the desired products in up to 99% yields with high regioselectivity.

  在室温下于无金属条件下，开发了一种用于合成6-未取代菲啶及其类似化合物的新型温和合成方法。该策略涉及二芳基甲基叠氮前体的串联叠氮重排/分子内环化及氧化反应，以高达99%的产率和高区域选择性获得目标产物。
• [EN] PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES MONOTERPÈNES
  申请人：NEONC TECHNOLOGIES INC

  公开号：WO2011109635A1

  公开（公告）日：2011-09-09

  The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w) The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w) The purified monoterpene can be used to treat a disease such as cancer The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

  本发明提供了一种用于纯化纯度大约高于98.5%（质量百分比）的单萜或倍半萜的过程。该过程包括将单萜（或倍半萜）衍生化以产生单萜（或倍半萜）衍生物，分离单萜（或倍半萜）衍生物，并从衍生物中释放单萜（或倍半萜）。本发明范围还涵盖了一种含有纯度大约高于98.5%（质量百分比）的单萜（或倍半萜）的药物组合物。纯化的单萜可用于治疗癌症等疾病。目前的单萜（或倍半萜）可以单独使用，也可以与放射线或其他治疗剂（如化疗药物）联合使用。